Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bendamustine Hydrochloride

FDA-approved product (powder, intravenous), marketed as Belrapzo, Bendamustine Hydrochloride, Bendeka and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Bendamustine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chronic lymphocytic leukemia
  • Neoplasm
  • Neoplasm of mature B-cells
  • Non-Hodgkins lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nitrogen mustard analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bendamustine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bendamustine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

    NCT07719855 · start 2026-07

    Registered record
    Registry ID
    NCT07719855
    Conditions
    Follicular Lymphoma ( FL)
    Interventions
    Orelabrutinib; obinutuzumab; Lenalidomide; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine; Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2033-12
    Enrolment
    652

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma ( FL)
    InterventionOrelabrutinib; obinutuzumab; Lenalidomide; Cyclophosphamide +4 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia

    NCT07169565 · start 2025-09-01

    Registered record
    Registry ID
    NCT07169565
    Conditions
    Waldenström Macroglobulinemia (WM)
    Interventions
    Ibrutinib; Bendamustine; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-09-01
    Completion
    2028-09-01
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenström Macroglobulinemia (WM)
    InterventionIbrutinib; Bendamustine; Rituximab
    PhasePhase 1
    Registry statusNot yet recruiting

  • BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

    NCT06854003 · start 2025-04-22

    Registered record
    Registry ID
    NCT06854003
    Conditions
    Mantle Cell Lymphoma; Lymphoma
    Interventions
    Bendamustine; Rituximab; Cytarabine; Zanubrutinib; Sonrotoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-22
    Completion
    2039-11-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma; Lymphoma
    InterventionBendamustine; Rituximab; Cytarabine; Zanubrutinib +1 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    NCT06549595 · start 2024-08-07

    Registered record
    Registry ID
    NCT06549595
    Conditions
    Untreated Follicular Lymphoma
    Interventions
    Surovatamig; R-CHOP; R-CVP; BR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-08-07
    Completion
    2031-11-26
    Enrolment
    1,018

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUntreated Follicular Lymphoma
    InterventionSurovatamig; R-CHOP; R-CVP; BR
    PhasePhase 3
    Registry statusRecruiting

  • BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

    NCT06477549 · start 2024-06-21

    Registered record
    Registry ID
    NCT06477549
    Conditions
    Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myeloproliferative Neoplasm; Myelodysplastic Syndromes
    Interventions
    Bendamustine Hydrochloride; Ruxolitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-06-21
    Completion
    2029-06
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma +2 more
    InterventionBendamustine Hydrochloride; Ruxolitinib
    PhasePhase 2
    Registry statusRecruiting

  • ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

    NCT06090864 · start 2024-04-25

    Registered record
    Registry ID
    NCT06090864
    Conditions
    Hodgkin Lymphoma; Relapse; Refractory
    Interventions
    Chemotherapy; Cell infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-04-25
    Completion
    2033-07-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma; Relapse; Refractory
    InterventionChemotherapy; Cell infusion
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

    NCT06241456 · start 2024-01-05

    Registered record
    Registry ID
    NCT06241456
    Conditions
    Advanced Solid Tumor
    Interventions
    FT825; Fludarabine; Cyclophosphamide; Bendamustine; Docetaxel; Cisplatin; Cetuximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-01-05
    Completion
    2044-05-01
    Enrolment
    351

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor
    InterventionFT825; Fludarabine; Cyclophosphamide; Bendamustine +3 more
    PhasePhase 1
    Registry statusRecruiting

  • A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

    NCT06170489 · start 2023-12-28

    Registered record
    Registry ID
    NCT06170489
    Conditions
    Hodgkin Lymphoma
    Interventions
    JS004 in combination with Toripalimab; Bendamustine or gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-28
    Completion
    2027-09-30
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHodgkin Lymphoma
    InterventionJS004 in combination with Toripalimab; Bendamustine or gemcitabine
    PhasePhase 3
    Registry statusRecruiting

  • Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

    NCT06006117 · start 2023-09-05

    Registered record
    Registry ID
    NCT06006117
    Conditions
    Marginal Zone Lymphoma
    Interventions
    Mosunetuzumab (SC); Rituximab (R); Bendamustine; CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone); Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-09-05
    Completion
    2032-09
    Enrolment
    260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMarginal Zone Lymphoma
    InterventionMosunetuzumab (SC); Rituximab (R); Bendamustine; CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) +1 more
    PhasePhase 3
    Registry statusRecruiting

  • Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

    NCT05287984 · start 2022-03-22

    Registered record
    Registry ID
    NCT05287984
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed
    Interventions
    Zanubrutinib, Fludarabine, cyclophosphamide and rituximab; Zanubrutinib, bendamustine, rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-03-22
    Completion
    2024-11-29
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed
    InterventionZanubrutinib, Fludarabine, cyclophosphamide and rituximab; Zanubrutinib, bendamustine, rituximab
    PhasePhase 2
    Registry statusUnknown

  • A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

    NCT04849715 · start 2022-03-11

    Registered record
    Registry ID
    NCT04849715
    Conditions
    Mantle Cell Lymphoma
    Interventions
    parsaclisib; rituximab; bendamustine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2022-03-11
    Completion
    2034-07-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    Interventionparsaclisib; rituximab; bendamustine; Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

    NCT04844866 · start 2021-08-18

    Registered record
    Registry ID
    NCT04844866
    Conditions
    Diffuse Large B-cell Lymphoma
    Interventions
    MB-CART2019.1; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-08-18
    Completion
    2031-09-30
    Enrolment
    213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B-cell Lymphoma
    InterventionMB-CART2019.1; Standard of Care
    PhasePhase 2
    Registry statusRecruiting

  • Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma

    NCT05006469 · start 2021-06-01

    Registered record
    Registry ID
    NCT05006469
    Conditions
    Bendamustine; Multiple Myeloma
    Interventions
    Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-06-01
    Completion
    2024-05-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBendamustine; Multiple Myeloma
    InterventionBendamustine
    PhasePhase 3
    Registry statusUnknown

  • DALY II USA/ MB-CART2019.1 for DLBCL

    NCT04792489 · start 2021-05-25

    Registered record
    Registry ID
    NCT04792489
    Conditions
    Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Transformed Lymphoma; Central Nervous System Lymphoma; Mantle Cell Lymphoma (MCL); Richter Transformation; Transplant-ineligible 2nd Line DLBCL
    Interventions
    zamtocabtagene autoleucel (MB-CART2019.1); Cyclophosphamide; Fludarabine; Bendamustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-05-25
    Completion
    2028-12-31
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B Cell Lymphoma; High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL) +5 more
    Interventionzamtocabtagene autoleucel (MB-CART2019.1); Cyclophosphamide; Fludarabine; Bendamustine
    PhasePhase 2
    Registry statusRecruiting

  • Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

    NCT04842318 · start 2021-03-01

    Registered record
    Registry ID
    NCT04842318
    Conditions
    Follicular Lymphoma
    Interventions
    BR for 6 cycles +R for 8 cycles; RCHOP for 6 cycles +R for 8 cycles; R2 for 6 cycles + R2 maintenance
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-03-01
    Completion
    2024-03-01
    Enrolment
    789

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFollicular Lymphoma
    InterventionBR for 6 cycles +R for 8 cycles; RCHOP for 6 cycles +R for 8 cycles; R2 for 6 cycles + R2 maintenance
    PhasePhase 4
    Registry statusUnknown